Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China

Wen-hua Liang, Wei-jie Guan, Cai-chen Li, Yi-min Li, Heng-rui Liang, Yi Zhao, Xiao-qing Liu, Ling Sang, Ru-chong Chen, Chun-li Tang, Tao Wang, Wei Wang, Qi-hua He, Zi-sheng Chen, Sook-San Wong, Mark Zanin, Jun Liu, Xin Xu, Jun Huang, Jian-fu Li, Li-min Ou, Bo Cheng, Shan Xiong, Zhan-hong Xie, Zheng-yi Ni, Yu Hu, Lei Liu, Hong Shan, Chun-liang Lei, Yi-xiang Peng, Li Wei, Yong Liu, Ya-hua Hu, Peng Peng, Jian-ming Wang, Ji-yang Liu, Zhong Chen, Gang Li, Zhi-jian Zheng, Shao-qin Qiu, Jie Luo, Chang-jiang Ye, Shao-yong Zhu, Lin-ling Cheng, Feng Ye, Shi-yue Li, Jin-ping Zheng, Nuo-fu Zhang, Nan-shan Zhong, Jian-xing He
European Respiratory Journal 2020; DOI: 10.1183/13993003.00562-2020
Wen-hua Liang
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
25joint first authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei-jie Guan
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
25joint first authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cai-chen Li
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
25joint first authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi-min Li
2Department of Pulmonary and Critical Care Medicine, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
25joint first authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heng-rui Liang
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
25joint first authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Zhao
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
25joint first authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiao-qing Liu
2Department of Pulmonary and Critical Care Medicine, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ling Sang
2Department of Pulmonary and Critical Care Medicine, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
3Wuhan Jin-yin tan Hospital, Wuhan, Hubei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ru-chong Chen
4Department of Respiratory Disease, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chun-li Tang
4Department of Respiratory Disease, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tao Wang
4Department of Respiratory Disease, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Wang
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qi-hua He
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zi-sheng Chen
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sook-San Wong
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Zanin
5School of Public Health, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Liu
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xin Xu
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Huang
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian-fu Li
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li-min Ou
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Cheng
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shan Xiong
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhan-hong Xie
4Department of Respiratory Disease, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zheng-yi Ni
3Wuhan Jin-yin tan Hospital, Wuhan, Hubei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu Hu
6Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lei Liu
7Shenzhen Third People's Hospital, Shenzhen, China
8The Second Affiliated Hospital of Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Shan
9The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chun-liang Lei
10Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi-xiang Peng
11The Central Hospital of Wuhan, Wuhan, Hubei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Wei
12Wuhan No.1 Hospital, Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, Hubei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yong Liu
13Chengdu Public Health Clinical Medical Center, Chengdu, Sichuan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ya-hua Hu
14Huangshi Central Hospital of Edong Healthcare Group, Affiliated Hospital of Hubei Polytechnic University, Huangshi, Hubei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peng Peng
15Wuhan Pulmonary Hospital, Wuhan, Hubei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian-ming Wang
16Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ji-yang Liu
17The First Hospital of Changsha, Changsha, Hunan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhong Chen
18The Third People's Hospital of Hainan Province, Sanya, Hainan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gang Li
19Huanggang Central Hospital, Huanggang, Hubei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhi-jian Zheng
20Wenling First People's Hospital, Wenling, Zhejiang, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shao-qin Qiu
21The Third People's Hospital of Yichang, Yichang, Hubei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jie Luo
22Affiliated Taihe Hospital of Hubei University of Medicine, Shiyan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chang-jiang Ye
23Xiantao First People's Hospital, Xiantao, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shao-yong Zhu
24The People's Hospital of Huangpi District, Wuhan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lin-ling Cheng
4Department of Respiratory Disease, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Feng Ye
4Department of Respiratory Disease, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shi-yue Li
4Department of Respiratory Disease, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
10Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jin-ping Zheng
4Department of Respiratory Disease, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nuo-fu Zhang
4Department of Respiratory Disease, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
6Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nan-shan Zhong
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian-xing He
1China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background During the outbreak of coronavirus disease 2019 (COVID-19), consistent and considerable differences in disease severity and mortality rate of patients treated in Hubei province compared to those in other parts of China has been observed. We sought to compare the clinical characteristics and outcomes of patients being treated inside and outside Hubei province, and explore the factors underlying these differences.

Methods Collaborating with the National Health Commission, we established a retrospective cohort to study hospitalised COVID-19 cases in China. Clinical characteristics, the rate of severe events and deaths, and the time to critical illness (invasive ventilation or intensive care unit admission or death) were compared between patients in and outside of Hubei. The impact of Wuhan-related exposure (a presumed key factor that drove the severe situation in Hubei, as Wuhan is the epicenter as well the administrative center of Hubei province) and the duration between symptom onset and admission on prognosis were also determined.

Results Upon data cut-off (Jan 31st, 2020), 1590 cases from 575 hospitals in 31 provincial administrative regions were collected (core cohort). The overall rate of severe cases and mortality was 16.0% and 3.2%, respectively. Patients in Hubei (predominantly with Wuhan-related exposure, 597/647, 92.3%) were older (mean: 49.7 versus 44.9 years), had more cases with comorbidity (32.9% versus 19.7%), higher symptomatic burden, abnormal radiologic manifestations, and, especially, a longer waiting time between symptom onset and admission (5.7 versus 4.5 days) compared with patients outside Hubei. Patients in Hubei [severe event rate 23.0% versus 11.1%, death rate 7.3% versus 0.3%, hazards ratio (HR) for critical illness 1.59, 95%CI 1.05–2.41] have a poorer prognosis compared with patients outside of Hubei after adjusting for age and comorbidity. However, among patients outside of Hubei, the duration from symptom onset to hospitalisation (mean: 4.4 versus 4.7 days) and prognosis (HR 0.84, 95%CI 0.40–1.80) were similar between patients with or without Wuhan-related exposure. In the overall population, the waiting time, but neither treated in Hubei nor Wuhan-related exposure, remained an independent prognostic factor (HR 1.05, 1.01–1.08).

Conclusion There were more severe cases and poorer outcomes for COVID-19 patients treated in Hubei, which might be attributed to the prolonged duration of symptom onset to hospitalisation in the epicenter. Future studies to determine the reason for delaying hospitalisation are warranted.

Abstract

This study highlights the necessity of urgent and vigorous support of healthcare resources and increased public awareness during the early stages of an outbreak of COVID-19 or similar diseases.

Introduction

A rapid outbreak of coronavirus disease 2019 (COVID-19) that arises from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, originates in Wuhan city, Hubei province in China and has become a global threat [1, 2]. COVID-19 can result in severe illnesses such as acute respiratory distress syndrome (ARDS), multiorgan dysfunction syndrome (MODS), and resultant death [1–3]. The World Health Organization (WHO) declared the SARS-CoV-2 a public health emergency of international concern on 30th Jan. As of February 16th, 2020, 58 873 laboratory-confirmed cases and 1699 deaths have been documented globally [4].

Considerable differences in disease severity and patient mortality in Hubei province with other parts of China have been documented [5]. Most primarily infected patients have been identified and treated in Hubei province, predominantly have close exposure to Wuhan. This is because Wuhan, the epicenter of COVID-19, is the administrative center of Hubei province and the majority of the population displaced from Wuhan have temporarily relocated to other areas of Hubei. But contrary to the initial wave of cases, an increasing number of patients have been diagnosed outside Wuhan and/or Hubei province, many of whom did not have close contact with people from Wuhan. These patients were more likely to have been infected by secondary or tertiary transmission of SARS-CoV-2. Other investigators have assumed that the high percentage of patients with Wuhan-related exposure (indicating potentially higher virulence) drove the severe situation in Hubei [6].

Exploring the difference between patients in and outside the highly endemic area, as well as by primary and progeny virus, may help clinicians better appreciate the evolution of SARS-CoV-2, and lead to more efficient allocation of healthcare resources. In addition, the exploration of the driving forces underlying these observations such as virus virulence and temporary shortage of health resources may help inform clinical practice and disease prevention. In this nationwide study, we sought to compare the clinical characteristics and outcomes of patients with COVID-19 between these populations, and explore the factors contributing to these differences.

Methods

Data sources

On behalf of the National Clinical Research Center for Respiratory Disease, and collaborating with the National Health Commission of the People's Republic of China, we have established a retrospective cohort to study the COVID-19 cases throughout China. We obtained medical records and compiled the data from laboratory-confirmed hospitalised cases with COVID-19 reported to the China National Health Commission between November 21st, 2019 and January 31st, 2020. The National Health Commission requested that all hospitals submit clinical records to the database. Hospitals whose clinical records had not been submitted by this deadline were requested again by the National Health Commission. Confirmed cases of COVID-19 were defined as patients who tested positive by high-throughput sequencing or real-time reverse-transcription polymerase-chain-reaction (RT-PCR) assay for nasal and pharyngeal swab specimens. Only laboratory-confirmed cases were included in our analysis.

Data extraction and processing

A team of experienced respiratory clinicians reviewed and abstracted the data. Data were entered into a computerised database and cross-checked. In the surveillance cohort, we included all patients in the daily report, with only the location and patient's clinical status (severity, live and discharge status). In the core cohort, baseline, examination and treatment information was available and collected. The recent exposure history, clinical symptoms and signs, and laboratory findings upon admission were extracted from electronic medical records. Radiologic assessments, including chest X-ray or computed tomography (CT), were performed based on the documentation/description in medical charts or combined with, if imaging films were available, a review by our medical staff. Major disagreement between two reviewers was resolved by consultation with the third reviewer. We defined the severity of COVID-19 (severe versus non-severe) based on the American Thoracic Society guidelines for community-acquired pneumonia given its extensive acceptance [7].

Patients with Wuhan-related exposure were defined as patients who lived in or recently travelled to Wuhan, or had recent close contact with people from Wuhan, confirmed by China centers for disease control and prevention (CDC) according to the self-report by patients and survey by the local CDC staff. We compared the differences in clinical characteristics and treatments. In terms of prognosis, the primary endpoint was critical illness including admission to the intensive care unit (ICU), or invasive ventilation, or death. We adopted this endpoint because admission to ICU, invasive ventilation, and death are serious outcomes of COVID-19 that have been adopted in a previous study to assess the severity of other serious infectious diseases, such as the avian influenza H7N9 virus [8]. Secondary endpoints consisted of the mortality rate, and the time from symptom onset to the critical illness and each of its components. We specifically examined the duration from symptom onset to admission.

Due to the great confounding impact of age and comorbidity on the prognosis of COVID-19, we sought to evaluate the prognostic effect of each candidate variable based on adjustment for age and comorbidity [including chronic obstructive pulmonary disease (COPD), diabetes mellitus, hypertension, coronary heart disease, cerebrovascular disease, viral hepatitis type B, malignant tumor, chronic kidney disease and immunodeficiency]. Therefore, we pre-planned several Cox regression analyses to evaluate the prognostic impact of 1) Hubei location alone; 2) Wuhan-related exposure alone; and 3) Wuhan-related exposure in patients outside Hubei. In addition, we planned to test a hypothesis that the time from symptom onset to hospitalisation might underly the difference in prognosis between the location and contact history. Thus, we included Hubei location, Wuhan-related exposure, time from symptom onset to hospitalisation, age and comorbidity in a Cox model.

Statistical analysis

Continuous variables were expressed as the means and standard deviations or medians and interquartile ranges (IQR) as appropriate. Categorical variables were summarised as the counts and percentages in each category. Wilcoxon rank-sum tests were applied to continuous variables, chi-square tests and Fisher's exact tests were used for categorical variables as appropriate. The risk of reaching to the critical illness and the potential risk factors were analysed using proportional hazard (PH) Cox regression models when PH assumption was not violated. We tested the PH assumption by modelling the log-log of survival curve using each variable included as strata, if the curve did not cross at all time points, the PH assumption was considered not violated. The hazards ratio (HR) along with the 95% confidence interval (95%CI) were reported. To visualise the probability of reaching critical illness of different categories, we presented the hazard function curves estimated by Cox regression model which have adjusted for all included confounders. The significance of the difference between the curves were obtained from the Cox regression model. Significance level was set at p value <0.05. All analyses were conducted with SPSS software version 23.0 (Chicago, IL, USA).

Role of the funding source

The funder had no role in the study design, data collection, analysis and interpretation, or writing of the report. The corresponding authors had full access to all data and had the final responsibility for the decision to submit for publication.

Results

Nationwide Epidemiology Surveillance of COVID-19

Up to January 31st, 2020, a total of 11 791 patients with laboratory-confirmed COVID-19 were identified in China. The flowchart of cohort establishment was shown in Figure S1. Of these, 7153 (60.7%) patients were identified in Hubei province. The severe cases accounted for 15.9% of the whole cohort, and 19.2% and 11.0% within and outside Hubei province, respectively. The overall mortality was 2.20% throughout China (3.48% in Hubei province, 0.22% outside Hubei province) (fig. 1). The latest data has shown a similar trend as of February 15, 2020 (Figure S1&2).

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Severe and deaths cases in China, inside Hubei and outside Hubei as of Jan 31, 2020. * The severe events and death events were reported by different statistic sources so that presented slight difference in total number.

Patient characteristics in the core cohort

In the core cohort, we have collected 1590 cases from 575 hospitals in 31 provincial administrative regions (full list in online supplement p4–9) upon data cut-off on Jan 31st. Our dataset covered 13.4% (1590/11791) of all cases being reported and covered 91.2% of regions (31/34) that had confirmed cases (fig. 2). Overall, the mean age was 48.9 years; 904 patients (57.3%) were males and 399 (25.1%) had coexisting conditions, including hypertension (269 [16.9%]), diabetes (130 [8.2%]), and cardiovascular disease (59 [3.7%]). Fever (88.0%), dry cough (70.2%), fatigue (42.8%), productive cough (36.0%), and shortness of breath (20.8%) were the most common symptoms. Most patients (71.1%) had abnormal chest CT manifestations. The overall rate of severe cases and mortality was 16.0% and 3.2%, respectively. Details were summarised in table 1.

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Shown are the official statistics of all documented laboratory-confirmed cases throughout China according to the National Health Commission (as of Jan 31st, 2020). The numerator denoted the number of patients being finally included in the data analysis for each province/autonomous region/provincial municipalities, while the denominator denoted the number of laboratory-confirmed cases for each province/autonomous region/provincial municipalities as reported by the National Health Commission.

View this table:
  • View inline
  • View popup
TABLE 1

Clinical characteristics and outcomes of patients with COVID-19 stratified by Hubei hospitalisation and Wuhan-related exposure

Patients treated inside Hubei and outside Hubei

As shown in table 1, 40.7% of the patients from the core dataset were hospitalised in Hubei province (647/1590). Most patients (597/647, 92.3%) in Hubei province had Wuhan-related exposure. Patients in Hubei province were older (mean: 55.1 versus 44.6 years) and had more cases with comorbidity (32.9% versus 19.7%). Patients in Hubei province had a higher symptomatic burden including fatigue (46.4% versus 40.3%), productive cough (40.2% versus 33.1%), shortness of breath (36.3% versus 10.2%), myalgia or arthralgia (20.3% versus 15.5%), nausea or vomiting (8.1% versus 4.2%), hemoptysis (2.3% versus 0.5%), and unconsciousness (2.7% versus 0.5%), but not pharyngalgia (11.3% versus 17.0%) compared to non-Hubei patients. Moreover, patients in Hubei province were more likely to have abnormal chest radiograph (18.1% versus 13.4%) and CT (74.7% versus 68.6%) manifestations. Patients in Hubei province also had a longer duration from symptom onset to hospitalisation (5.7 versus 4.5 days) compared with patients outside of Hubei province.

Patient with versus without Wuhan-related exposure

The majority of patients (1334/1590, 83.9%) in this dataset had Wuhan exposure history (18.1% lived in Wuhan, 36.7% recently travelled to Wuhan, and 45.1% had recent contact with people from Wuhan). Compared with those that had no exposure to Wuhan, Wuhan-exposed patients were significantly older (mean: 49.7 versus 44.9 years) and had more cases with comorbidity (26.3% versus 18.8%, p=0.012), including hypertension (18.1% versus 10.5%), diabetes (8.8% versus 4.7%), and malignancy (1.3% versus 0%); fever (88.0% versus 87.7%), fatigue (43.2% versus 40.7%), and shortness of breath (21.8% versus 15.6%). Furthermore, abnormal manifestation in chest radiograph (16.2% versus 10.5%) and CT (71.9% versus 66.8%) were more commonly seen in patients with Wuhan-related exposure than their counterparts. Table 1 summarised detailed information.

Patient with versus without Wuhan-related exposure outside Hubei

Of 943 patients outside of Hubei province, 737 (78.2%) reported Wuhan-related exposure. There were no differences in patient's clinical characteristics, signs, comorbidities, the rate of abnormal chest images, and most symptoms between patients with and without Wuhan-related exposure. However, Wuhan-related patients reported less productive cough (30.5% versus 43.8%) and shortness of breath (8.7% versus 15.5%) than their counterparts. See details in table 2. The duration from symptom onset to hospitalisation was similar between patients with and without Wuhan-related exposure (mean: 4.4 versus 4.7 years) treated outside of Hubei province.

View this table:
  • View inline
  • View popup
TABLE 2

Clinical characteristics and outcomes of patients with COVID-19 with or without Wuhan-related exposure outside Hubei

Prognostic analyses

As shown in figure 3, both patients treated in Hubei province (23.0% versus 11.1%, p<0.001) and those with Wuhan-related exposure (16.9% versus 11.3%, p=0.026) had more severe or fatal cases compared to their counterparts. Similarly, Hubei patients (7.3% versus 0.3%, p<0.001) and patients with Wuhan-related exposure (3.6% versus 0.8%, p=0.017) had a higher mortality rate. After adjusting for age and comorbidity, the Cox regression model without PH assumption violation revealed that patients in Hubei province (HR 1.59, 95%CI 1.05–2.41; p=0.027, fig. 4a) and those with Wuhan exposure history (HR 1.34, 95%CI 0.70–2.57; p=0.385, fig. 4b) were more likely to reach critical illness. Details were summarised in Table S1–3.

FIGURE 3
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3

Severe and deaths cases in Hubei and outside Hubei, Wuhan-related exposure versus no Wuhan-related exposure.

FIGURE 4
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4

a) The time-dependent risk of reaching to the critical illness between patients in and outside Hubei province; (b) The time-dependent risk of reaching to the critical illness between patients with and without Wuhan-related exposure; (c) The time-dependent risk of reaching to the critical illness among patients in Hubei province who had Wuhan-related exposure, patients outside Hubei province who had Wuhan-related exposure, and patients outside Hubei province who did not have a Wuhan-related exposure; (d) The time-dependent risk of reaching to the critical illness between patients treated outside Hubei with and without Wuhan-related exposure.

We further subdivided patients with Wuhan-related exposure according to the location of hospitals. Patients with Wuhan exposure history who underwent treatment outside of Hubei province had a better prognosis compared with those treated in Hubei (HR 0.57, 95%CI 0.36–0.91, p=0.018, fig. 4c), and yielded similar outcomes compared with patients with no Wuhan exposure history (HR 0.84, 95%CI 0.40–1.80, p=0.653, fig. 4c and d). Most importantly, after being included in the Cox regression model, the duration from symptom onset to hospitalisation, but not Hubei or Wuhan-related exposure, remained an independent factor of the prognosis among the general population (HR 1.05, 1.01–1.08, p=0.005) (table 3).

View this table:
  • View inline
  • View popup
TABLE 3

Hazard ratios estimated by multivariate proportional hazard Cox model

Discussion

Although the pandemic has lessened in China and the results reported here focused on the early stage of the outbreak, an increasing number of patients have been diagnosed outside China and some other areas have become new epicenters, such as Lombardia, Italy and Madrid, Spain. Summarising the experience from China and providing in-depth understanding of the situation in the previous epicenter can help to improve the strategy in the current epicenters. For the situation outside of the epicenter Hubei, two studies presented characteristics and outcomes among patients outside Hubei in Shenzhen and Zhejiang, however, the sample size is small therefore, comparison to Hubei patients cannot be performed [9, 10]. To our knowledge, this is the first nationwide study in China investigating the differences in the clinical characteristics and the prognosis of patients with COVID-19 between both those in and outside of Hubei province, and those with and without Wuhan-related exposure. We believe that our core cohort could partially represent the overall situation as of Jan 31st, taking into account the patient number (13.4% of all cases) and the broad coverage (covering almost all major provinces/cities/autonomous regions). Moreover, this dataset showed consistent epidemiological characteristics with the surveillance dataset, indicating that it represented the real-world conditions.

Compared with those with contact history with people from Wuhan or living in Hubei province, patients without Wuhan-related exposure or living outside of Hubei were younger, had fewer comorbidities, less abnormal chest radiographic manifestations, and slightly lower symptom burden. These findings suggested a potentially augmented infectivity in the general population beyond fragile individuals (i.e., the elderly). This is in agreement with the median reproduction number (R0), which has increased from 2.0 in early studies to 3.8 in more recent studies [11, 12]. In addition, viral genome sequencing of cases from Hubei province and other regions/countries has also lent support to the continuous revolution in the viral functional regions that facilitates its transmission among the human population (self-adaptation) [13]. However, we should be cautious about the bias resulting from the undiagnosed cases in the early phase of transmission when most people were not aware of this disease.

It has been believed that the onward transmission of a virus might result in attenuated disease [14, 15]. Our results showed fewer severe events and a lower mortality rate among patients outside of Hubei province and patients that had no history of Wuhan-related exposure. However, these results might have been biased by the temporary shortage of health resources, such as the limited hospital performance and detection capacity, that resulted from the sudden outbreak of COVID-19 in Hubei. After the surge of cases in January 2020, hospitals in Hubei province were heavily overloaded and managed an overwhelming increase in the number of patients. These shortages could have led to a delay in the diagnosis and treatment of patients, which further contributed to the worsening of overall status upon admission and an increased risk of death.

In this study, we have included the duration from symptom onset to admission to evaluate the impact of the healthcare capacity on the difference between Hubei and other regions in China. Significantly longer waiting time was observed among patients in Hubei province, whereas patients with or without Wuhan-related exposure shared similar waiting time outside of Hubei province. Importantly, we have found that the prolonged waiting time, rather than the geographic location or the Wuhan-related exposure history, predicted the clinical prognosis of COVID-19. We speculated that some patients from Wuhan travelled to other cities outside of Hubei province seeking more timely treatment. These patients reported a similar waiting time and medical care records, which translated into a similar prognosis with the local residents. Consistently, the incidence of severe cases and mortality continuously decreased (figure S1) since clinicians, nurses, and medical instruments have been dispatched to Hubei province. On the other hand, timely screening of candidates with suspected symptoms or contact with confirmed cases might help promptly initiate medical care, thus preventing further spreading of the disease.

There are some limitations of this study. First, although we made every effort to collect data from all patients, some hospitals did not answer our request. Thus, although the dataset had a broad coverage of all patients and regions, the non-responsive bias cannot be fully excluded. Second, the date of symptom onset is self-report based, bias from patient recall might exist. Third, we cannot evaluate the exact healthcare capacity of each hospital but used a duration from symptom onset to admission as an indirect measure. Fourth, only a small proportion of patients had Wuhan exposure history, which may give a non-balanced result with some possible bias. Fifth, some other factors that may have impact on the prognosis, e.g. secondary infection, cannot be evaluated in this study. In addition, a significant proportion of people infected by the SARS-CoV-2 are asymptomatic and were not included in this study of hospitalised patients, the situation in the general infected population requires further studies.

Our findings indicate that the temporary shortage in health capacity in the outbreak epicenter, rather than the transmission history, has resulted in the large number of severe cases or deaths in Hubei province. These results have expanded our understanding of patients infected by secondary or tertiary transmission which will account for the majority of patients that are infected worldwide, and provided timely and important implications for basic research and establishing public health policy. Adequate management of health care resources as well as the public's response is important to mitigate the impact of the outbreak. This study highlights the necessity of urgent and vigorous support of healthcare resources and increased public awareness during the early stages of an outbreak of COVID-19 or similar diseases.

Acknowledgements

We thank the hospital staff (see Supplementary Appendix for a full list of the staff) for their efforts in collecting the information. We are indebted to the coordination of Drs. Zong-jiu Zhang, Ya-hui Jiao, Bin Du, Xin-qiang Gao and Tao Wei (National Health Commission), Yu-fei Duan and Zhi-ling Zhao (Health Commission of Guangdong Province), Yi-min Li, Zi-jing Liang, Nuo-fu Zhang, Shi-yue Li, Qing-hui Huang, Wen-xi Huang and Ming Li (Guangzhou Institute of Respiratory Health) which greatly facilitate the collection of patient's data. Special thanks are given to the statistical team members Prof. Zheng Chen, Drs. Dong Han, Li Li, Zheng Chen, Zhi-ying Zhan, Jin-jian Chen, Li-jun Xu, Xiao-han Xu (State Key Laboratory of Organ Failure Research, Department of Biostatistics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University). We also thank Li-qiang Wang, Wei-peng Cai, Zi-sheng Chen (the sixth affiliated hospital of Guangzhou medical university), Chang-xing Ou, Xiao-min Peng, Si-ni Cui, Yuan Wang, Mou Zeng, Xin Hao, Qi-hua He, Jing-pei Li, Xu-kai Li, Wei Wang, Li-min Ou, Ya-lei Zhang, Jing-wei Liu, Xin-guo Xiong, Wei-juna Shi, San-mei Yu, Run-dong Qin, Si-yang Yao, Bo-meng Zhang, Xiao-hong Xie, Zhan-hong Xie, Wan-di Wang, Xiao-xian Zhang, Hui-yin Xu, Zi-qing Zhou, Ying Jiang, Ni Liu, Jing-jing Yuan, Zheng Zhu, Jie-xia Zhang, Hong-hao Li, Wei-hua Huang, Lu-lin Wang, Jie-ying Li, Li-fen Gao, Jia-bo Gao, Cai-chen Li, Xue-wei Chen, Jia-bo Gao, Ming-shan Xue, Shou-xie Huang, Jia-man Tang, Wei-li Gu, Jin-lin Wang (Guangzhou Institute of Respiratory Health) for their dedication to data entry and verification. Finally, we thank all the patients who consented to donate their data for analysis and the medical staffs working in the front line.

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • This study is approved by the ethics committee of the First Affiliated Hospital of Guangzhou Medical University.

  • Support statement: Supported by National Health Commission, National Natural Science Foundation, Department of Science and Technology of Guangdong Province. National Natural Science Foundation of China; DOI: http://dx.doi.org/10.13039/501100001809; Grant: 81871893; Guangdong Science and Technology Department; DOI: http://dx.doi.org/10.13039/501100007162; Grant: 201804020030.

  • Conflict of interest: Dr. Liang has nothing to disclose.

  • Conflict of interest: Dr. Guan has nothing to disclose.

  • Conflict of interest: Dr. Li has nothing to disclose.

  • Conflict of interest: Dr. Li has nothing to disclose.

  • Conflict of interest: Dr. Liang has nothing to disclose.

  • Conflict of interest: Dr. Zhao has nothing to disclose.

  • Conflict of interest: Dr. Liu has nothing to disclose.

  • Conflict of interest: Dr. Sang has nothing to disclose.

  • Conflict of interest: Dr. Chen has nothing to disclose.

  • Conflict of interest: Dr. Tang has nothing to disclose.

  • Conflict of interest: Dr. Wang has nothing to disclose.

  • Conflict of interest: Dr. Wang has nothing to disclose.

  • Conflict of interest: Dr. He has nothing to disclose.

  • Conflict of interest: Dr. Chen has nothing to disclose.

  • Conflict of interest: Dr. Wong has nothing to disclose.

  • Conflict of interest: Dr. Zanin has nothing to disclose.

  • Conflict of interest: Dr. Liu has nothing to disclose.

  • Conflict of interest: Dr. Xu has nothing to disclose.

  • Conflict of interest: Dr. Huang has nothing to disclose.

  • Conflict of interest: Dr. Li has nothing to disclose.

  • Conflict of interest: Dr. Ou has nothing to disclose.

  • Conflict of interest: Dr. Cheng has nothing to disclose.

  • Conflict of interest: Dr. Xiong has nothing to disclose.

  • Conflict of interest: Dr. Xie has nothing to disclose.

  • Conflict of interest: Dr. Ni has nothing to disclose.

  • Conflict of interest: Dr. Hu has nothing to disclose.

  • Conflict of interest: Dr. Liu has nothing to disclose.

  • Conflict of interest: Dr. Shan has nothing to disclose.

  • Conflict of interest: Dr. Lei has nothing to disclose.

  • Conflict of interest: Dr. Peng has nothing to disclose.

  • Conflict of interest: Dr. Wei has nothing to disclose.

  • Conflict of interest: Dr. Liu has nothing to disclose.

  • Conflict of interest: Dr. Hu has nothing to disclose.

  • Conflict of interest: Dr. Peng has nothing to disclose.

  • Conflict of interest: Dr. Wang has nothing to disclose.

  • Conflict of interest: Dr. Liu has nothing to disclose.

  • Conflict of interest: Dr. Chen has nothing to disclose.

  • Conflict of interest: Dr. Li has nothing to disclose.

  • Conflict of interest: Dr. Zheng has nothing to disclose.

  • Conflict of interest: Dr. Qiu has nothing to disclose.

  • Conflict of interest: Dr. Luo has nothing to disclose.

  • Conflict of interest: Dr. Ye has nothing to disclose.

  • Conflict of interest: Dr. Zhu has nothing to disclose.

  • Conflict of interest: Dr. Cheng has nothing to disclose.

  • Conflict of interest: Dr. Ye has nothing to disclose.

  • Conflict of interest: Dr. Li has nothing to disclose.

  • Conflict of interest: Dr. Zheng has nothing to disclose.

  • Conflict of interest: Dr. Zhang has nothing to disclose.

  • Conflict of interest: Dr. Zhong has nothing to disclose.

  • Conflict of interest: Dr. He has nothing to disclose.

  • Received March 5, 2020.
  • Accepted March 29, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Huang C,
    2. Wang Y,
    3. Li X, et al.
    Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506. doi:10.1016/S0140-6736(20)30183-5
    OpenUrlCrossRefPubMed
  2. ↵
    1. Chen N,
    2. Zhou M,
    3. Dong X, et al.
    Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507–513. doi:10.1016/S0140-6736(20)30211-7
    OpenUrlCrossRefPubMed
  3. ↵
    1. Wang C,
    2. Horby PW,
    3. Hayden FG, et al.
    A novel coronavirus outbreak of global health concern. Lancet 2020; 395: 470–473. doi:10.1016/S0140-6736(20)30185-9
    OpenUrl
  4. ↵
    www.who.int. Date last accessed: Feb 17, 2020.
  5. ↵
    https://static.wecity.qq.com/wuhan-haiwai-pre/dist/index.html#/. Date last accessed: Feb 17, 2020.
  6. ↵
    1. Tang X,
    2. Wu C,
    3. Li X, et al.
    On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev 2020.
  7. ↵
    1. Metlay JP,
    2. Waterer GW,
    3. Long AC, et al.
    Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200: e45–e67. doi:10.1164/rccm.201908-1581ST
    OpenUrlCrossRef
  8. ↵
    1. Cai Q-X,
    2. Huang D-L,
    3. Ou P-C, et al.
    COVID-19 in a Designated Infectious Diseases Hospital Outside Hubei Province, China. medRxiv 2020. published online Feb 19. doi:10.1101/2020.02.17.20024018v1 (preprint).
  9. ↵
    1. Xu X-W,
    2. Wu X-X,
    3. Jiang X-G, et al.
    Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020; 368: m606. doi:10.1136/bmj.m606
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.
  11. ↵
    1. Gao H-N,
    2. Lu H-Z,
    3. Cao B, et al.
    Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368: 2277–2285. doi:10.1056/NEJMoa1305584
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Li Q,
    2. Guan X,
    3. Wu P, et al.
    Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020; 382: 1199–1207. doi:10.1056/NEJMoa2001316
    OpenUrlCrossRefPubMed
  13. ↵
    1. Yang Y,
    2. Lu Q,
    3. Liu M, et al.
    Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv 2020. published online Feb 11. doi:10.1101/2020.02.10.20021675 (preprint).
  14. ↵
    1. Kim Y-S,
    2. Aigerim A,
    3. Park U, et al.
    Sequential Emergence and Wide Spread of Neutralization Escape Middle East Respiratory Syndrome Coronavirus Mutants, South Korea, 2015. Emerging Infect Dis 2019; 25: 1161–1168. doi:10.3201/eid2506.181722
    OpenUrlCrossRefPubMed
  15. ↵
    1. Li X,
    2. Wang W,
    3. Zhao X, et al.
    Transmission dynamics and evolutionary history of 2019-nCoV. J Med Virol 2020; 92: 501–511. doi:10.1002/jmv.25701
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 61 Issue 2 Table of Contents
European Respiratory Journal: 61 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China
Wen-hua Liang, Wei-jie Guan, Cai-chen Li, Yi-min Li, Heng-rui Liang, Yi Zhao, Xiao-qing Liu, Ling Sang, Ru-chong Chen, Chun-li Tang, Tao Wang, Wei Wang, Qi-hua He, Zi-sheng Chen, Sook-San Wong, Mark Zanin, Jun Liu, Xin Xu, Jun Huang, Jian-fu Li, Li-min Ou, Bo Cheng, Shan Xiong, Zhan-hong Xie, Zheng-yi Ni, Yu Hu, Lei Liu, Hong Shan, Chun-liang Lei, Yi-xiang Peng, Li Wei, Yong Liu, Ya-hua Hu, Peng Peng, Jian-ming Wang, Ji-yang Liu, Zhong Chen, Gang Li, Zhi-jian Zheng, Shao-qin Qiu, Jie Luo, Chang-jiang Ye, Shao-yong Zhu, Lin-ling Cheng, Feng Ye, Shi-yue Li, Jin-ping Zheng, Nuo-fu Zhang, Nan-shan Zhong, Jian-xing He
European Respiratory Journal Jan 2020, 2000562; DOI: 10.1183/13993003.00562-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China
Wen-hua Liang, Wei-jie Guan, Cai-chen Li, Yi-min Li, Heng-rui Liang, Yi Zhao, Xiao-qing Liu, Ling Sang, Ru-chong Chen, Chun-li Tang, Tao Wang, Wei Wang, Qi-hua He, Zi-sheng Chen, Sook-San Wong, Mark Zanin, Jun Liu, Xin Xu, Jun Huang, Jian-fu Li, Li-min Ou, Bo Cheng, Shan Xiong, Zhan-hong Xie, Zheng-yi Ni, Yu Hu, Lei Liu, Hong Shan, Chun-liang Lei, Yi-xiang Peng, Li Wei, Yong Liu, Ya-hua Hu, Peng Peng, Jian-ming Wang, Ji-yang Liu, Zhong Chen, Gang Li, Zhi-jian Zheng, Shao-qin Qiu, Jie Luo, Chang-jiang Ye, Shao-yong Zhu, Lin-ling Cheng, Feng Ye, Shi-yue Li, Jin-ping Zheng, Nuo-fu Zhang, Nan-shan Zhong, Jian-xing He
European Respiratory Journal Jan 2020, 2000562; DOI: 10.1183/13993003.00562-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung volumes and survival in chronic lung allograft dysfunction
  • Factors associated with FEV1 decline in CF
  • Serum uric acid as a predictor of COPD exacerbations
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society